COPD News

Odds for asthma symptoms, COPD and chronic bronchitis went up if individuals reported earlier “often/always” vs. “never” gum bleeding, according to a poster presented at the European Respiratory Society International Congress.

Dupilumab’s impact on exacerbation rate and lung function in adults with COPD and type 2 inflammation did not differ based on BODE index score, according to a poster presented at the European Respiratory Society International Congress.

In the first half of 2024, several U.S. health care professionals discussed the price of inhalers for patients with COPD on X, formerly Twitter, according to a tracker from Creation Healthcare.

Adults with asthma and/or COPD who received 23 text messages about preventer inhaler use over 26 weeks had improved inhaler adherence, according to a poster presented at the European Respiratory Society International Congress.

Patients with COPD experience changes in voice pitch and jitter during the onset and peak of an exacerbation, according to a poster presented at the European Respiratory Society International Congress.

Receiving itepekimab led to a 51% lower adjusted annualized exacerbation rate in former smokers with moderate/severe COPD and exacerbation history, according to a poster presented at the European Respiratory Society International Congress.

At 52 weeks, adults with moderate/severe COPD and type 2 inflammation receiving dupilumab vs. placebo showed more improved symptom scores, according to a poster presented at the European Respiratory Society International Congress.

Air pollution and genetic susceptibility increased the risks for progression from asthma to COPD, according to a study presented at the European Respiratory Society International Congress.

Dupilumab led to improvement and was safe in adults with moderate to severe COPD and type 2 inflammation at week 52, according to a pooled analysis of BOREAS and NOTUS presented at the European Respiratory Society International Congress.